Table 4 Meta-analysis of the association between XRCC1 Arg399Gln polymorphism and platinum-based chemotherapy in objective response rate, overall survival and median progression-free survival for advanced lung cancer patients.

From: Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy

Genetic comparisons

Study groups

No. of studiesa

Test of association

P-value

Model

Test of heterogeneity

ORb/HRc (95% CI)

Z

χ2

P-value

I2(%)

Objective response rate(OR)

 GlnGln vs. ArgArg

Overall

26

0.75(0.47–1.20)

1.22

0.223

R

77.93

<0.001

67.9

Populations

        

Asian

23

0.68(0.39–1.18)

1.38

0.169

R

74.2

<0.001

70.4

Caucasian

3

1.06(0.50–2.24)

0.14

0.889

R

3.61

0.165

44.6

QS

        

High quality

20

0.85(0.51–1.42)

0.61

0.541

R

69.57

<0.001

72.7

Low quality

6

0.36(0.14–0.94)

2.08

0.037

R

1.55

0.907

0

 GlnArg vs. ArgArg

Overall

26

0.80(0.62–1.02)

1.79

0.074

R

66.61

<0.001

62.5

Populations

        

Asian

23

0.80(0.60–1.06)

1.57

0.117

R

64.46

<0.001

65.9

Caucasian

3

0.73(0.48–1.09)

1.54

0.123

R

0.34

0.844

0

QS

        

High quality

20

0.86(0.66–1.13)

1.08

0.278

R

52.26

<0.001

63.6

Low quality

6

0.50(0.24–1.02)

1.91

0.057

R

9.89

0.078

49.5

 GlnGln+GlnArg vs. ArgArg

Overall

38

0.68(0.54–0.86)

3.20

0.001

R

130.81

<0.001

71.7

Populations

        

Asian

33

0.65(0.50– 0.86)

3.03

0.002

R

130.43

<0.001

75.50

Caucasian

5

0.80(0.58–1.10)

1.41

0.158

R

0.17

0.996

0

QS

        

High quality

28

0.72(0.56–0.94)

2.4

0.017

R

106.56

<0.001

74.7

Low quality

10

0.53(0.32–0.89)

2.39

0.017

R

19.08

0.025

52.8

 GlnGln vs. GlnArg+ArgArg

Overall

26

0.85(0.58–1.25)

0.81

0.415

R

59.09

<0.001

57.7

Populations

        

Asian

23

0.78(0.50–1.21)

1.11

0.268

R

54.3

<0.001

59.5

Caucasian

3

1.21(0.54–2.70)

0.46

0.647

R

4.75

0.093

57.9

QS

        

High quality

20

0.92(0.60–1.40)

0.41

0.685

R

54.83

<0.001

65.3

Low quality

6

0.48(0.19–1.21)

1.56

0.119

R

0.27

0.998

0

 Gln vs. Arg

Overall

26

0.80(0.63–1.01)

1.87

0.061

R

119.97

<0.001

79.2

Populations

        

Asian

23

0.78(0.59–1.01)

1.87

0.062

R

117.97

<0.001

81.4

Caucasian

3

0.94(0.72–1.24)

0.43

0.670

R

1.65

0.438

0

QS

        

High quality

20

0.86(0.66–1.11)

1.15

0.251

R

105.25

<0.001

81.9

Low quality

6

0.62(0.43–0.90)

2.51

0.012

R

6.11

0.296

18.2

Overall survival(HR)

 GlnGln vs. ArgArg

Overall

14

1.14(0.75–1.75)

0.62

0.533

R

58.1

<0.001

77.6

Populations

        

Asian

10

0.90(0.57–1.43)

0.43

0.666

R

29.53

0.001

69.5

Caucasian

4

1.91(0.77–4.73)

1.4

0.161

R

21.45

<0.001

86

 GlnGln+GlnArg vs. ArgArg

Overall

8

0.84(0.64–1.09)

1.33

0.183

R

20.56

0.004

65.9

Populations

        

Asian

7

0.81(0.60–1.09)

1.38

0.166

R

20.19

0.003

70.3

Caucasian

1

1.01(0.66–1.55)

0.05

0.963

R

—

—

—

QS

        

High quality

7

0.85(0.63–1.15)

1.08

0.282

R

19.58

0.003

69.3

Low quality

1

0.74(0.50–1.10)

1.48

0.139

R

20.56

0.004

65.9

 GlnArg vs. ArgArg

Overall

13

0.91(0.75–1.10)

0.96

0.337

R

32.21

0.001

62.7

Populations

        

Asian

9

0.84(0.66–1.08)

1.38

0.166

R

23.55

0.003

66

Caucasian

4

1.07(0.77–1.47)

0.38

0.701

R

6.93

0.074

56.7

 GlnGln vs. GlnArg

Overall

3

1.42(1.01–2.00)

2.03

0.043

F

0.67

0.714

0

Populations

        

Asian

1

1.20(0.71–2.03)

0.68

0.498

F

—

—

—

Caucasian

2

1.60(1.03–2.50)

2.08

0.038

F

0

0.978

0

Median progression-free survival(HR)

 GlnGln vs. ArgArg

Overall

4

0.80(0.58–1.11)

1.34

0.179

F

3.53

0.317

14.9

Populations

        

Asian

3

0.72(0.48–1.08)

1.58

0.114

F

2.83

0.243

29.2

Caucasian

1

0.97(0.55–1.70)

0.11

0.915

F

—

—

—

 GlnArg vs. ArgArg

Overall

3

0.91(0.71–1.17)

0.73

0.468

F

1.96

0.376

0

 GlnGln+GlnArg vs. ArgArg

Overall

4

0.86(0.70–1.06)

1.38

0.166

F

1.69

0.638

0

Populations

        

Asian

3

0.87(0.68–1.12)

1.09

0.277

F

1.65

0.438

0

Caucasian

1

0.83(0.55–1.26)

0.88

0.378

F

—

—

—

  1. Note: OR, odds ratio; HR: hazard ratio; CI, confidence interval; vs., versus; QS: quality score; GlnGln vs. ArgArg: Homozygote comparison; GlnArg vs. ArgArg: Heterozygote comparison; GlnGln+GlnArg vs. ArgArg: Dominant model; GlnGln vs. GlnArg+ArgArg: Recessive model; Gln vs. Arg: Allele contrast; F, fixed effect model; R, random effect model; Random effect model was chosen when P-value < 0.10 and/or I2 > 50% for heterogeneity test; otherwise fixed effect model was used.
  2. aThe detailed references are given in Table 1.
  3. bThe OR for objective response rate.
  4. cThe HR for overall survival and median progression-free survival.
Back to article page